These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2390 related items for PubMed ID: 26452628

  • 1. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma.
    Li X, Yao W, Yuan Y, Chen P, Li B, Li J, Chu R, Song H, Xie D, Jiang X, Wang H.
    Gut; 2017 Jan; 66(1):157-167. PubMed ID: 26452628
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A Natural CCR2 Antagonist Relieves Tumor-associated Macrophage-mediated Immunosuppression to Produce a Therapeutic Effect for Liver Cancer.
    Yao W, Ba Q, Li X, Li H, Zhang S, Yuan Y, Wang F, Duan X, Li J, Zhang W, Wang H.
    EBioMedicine; 2017 Aug; 22():58-67. PubMed ID: 28754304
    [Abstract] [Full Text] [Related]

  • 5. CCL2/CCR2 axis induces hepatocellular carcinoma invasion and epithelial-mesenchymal transition in vitro through activation of the Hedgehog pathway.
    Zhuang H, Cao G, Kou C, Liu T.
    Oncol Rep; 2018 Jan; 39(1):21-30. PubMed ID: 29115520
    [Abstract] [Full Text] [Related]

  • 6. CCL2-CCR2 axis recruits tumor associated macrophages to induce immune evasion through PD-1 signaling in esophageal carcinogenesis.
    Yang H, Zhang Q, Xu M, Wang L, Chen X, Feng Y, Li Y, Zhang X, Cui W, Jia X.
    Mol Cancer; 2020 Feb 27; 19(1):41. PubMed ID: 32103760
    [Abstract] [Full Text] [Related]

  • 7. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL, Zhou ZJ, Hu ZQ, Huang XW, Wang Z, Chen EB, Fan J, Cao Y, Dai Z, Zhou J.
    Gastroenterology; 2016 Jun 27; 150(7):1646-1658.e17. PubMed ID: 26924089
    [Abstract] [Full Text] [Related]

  • 8. Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients.
    Chew V, Tow C, Teo M, Wong HL, Chan J, Gehring A, Loh M, Bolze A, Quek R, Lee VK, Lee KH, Abastado JP, Toh HC, Nardin A.
    J Hepatol; 2010 Mar 27; 52(3):370-9. PubMed ID: 19720422
    [Abstract] [Full Text] [Related]

  • 9. Interleukin-8 Induces Expression of FOXC1 to Promote Transactivation of CXCR1 and CCL2 in Hepatocellular Carcinoma Cell Lines and Formation of Metastases in Mice.
    Huang W, Chen Z, Zhang L, Tian D, Wang D, Fan D, Wu K, Xia L.
    Gastroenterology; 2015 Oct 27; 149(4):1053-67.e14. PubMed ID: 26065367
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice.
    Li G, Liu D, Kimchi ET, Kaifi JT, Qi X, Manjunath Y, Liu X, Deering T, Avella DM, Fox T, Rockey DC, Schell TD, Kester M, Staveley-O'Carroll KF.
    Gastroenterology; 2018 Mar 27; 154(4):1024-1036.e9. PubMed ID: 29408569
    [Abstract] [Full Text] [Related]

  • 15. Repolarization of Immunosuppressive Macrophages by Targeting SLAMF7-Regulated CCL2 Signaling Sensitizes Hepatocellular Carcinoma to Immunotherapy.
    Weng J, Wang Z, Hu Z, Xu W, Sun JL, Wang F, Zhou Q, Liu S, Xu M, Xu M, Gao D, Shen YH, Yi Y, Shi Y, Dong Q, Zhou C, Ren N.
    Cancer Res; 2024 Jun 04; 84(11):1817-1833. PubMed ID: 38484085
    [Abstract] [Full Text] [Related]

  • 16. Tumor-associated macrophages promote cancer stem cell-like properties via transforming growth factor-beta1-induced epithelial-mesenchymal transition in hepatocellular carcinoma.
    Fan QM, Jing YY, Yu GF, Kou XR, Ye F, Gao L, Li R, Zhao QD, Yang Y, Lu ZH, Wei LX.
    Cancer Lett; 2014 Oct 01; 352(2):160-8. PubMed ID: 24892648
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer.
    Schneider C, Teufel A, Yevsa T, Staib F, Hohmeyer A, Walenda G, Zimmermann HW, Vucur M, Huss S, Gassler N, Wasmuth HE, Lira SA, Zender L, Luedde T, Trautwein C, Tacke F.
    Gut; 2012 Dec 01; 61(12):1733-43. PubMed ID: 22267597
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 120.